Recently, a phase II trial in patients with locally advanced pancreatic cancer has shown that addition of losartan to chemoradiation enhanced tumor shrinkage and enabled more margin negative resections likely due to interfering with TGF-β signaling in CAFs which are characteristic of the desmoplastic tumor microenvironment in pancreatic cancer (254). The gene discussed is TGFB1; the disease is neoplasm.